Recruiting

Developing an AI Pharmacy Chatbot for the Population of Hong Kong

The primary objective of this study is to is to develop a conversational AI service (chatbot) in Hong Kong to assist patients and caregivers with inquires related to Hospital Authority (HA)-prescribed medications, and to evaluate its effectiveness in answering medication-related questions. The main questions it aims to answer are: 1. How satisfied are the patients and caregivers with this pharmacy chatbot? 2. How will the pharmacy chatbot impact eligible patients or caregivers on their (or the patient they are…

ClinicalTrials.gov IDNCT07037563
PhaseNA
Enrollment280
SponsorThe University of Hong Kong
Age18 Years and older
SexALL
I'm interested View official listing

Conditions studied

Hyperglycaemia, Hypertension, Hyperlipidaemia, Artificial Intelligence (AI)

About this study

The primary objective of this study is to is to develop a conversational AI service (chatbot) in Hong Kong to assist patients and caregivers with inquires related to Hospital Authority (HA)-prescribed medications, and to evaluate its effectiveness in answering medication-related questions. The main questions it aims to answer are: 1. How satisfied are the patients and caregivers with this pharmacy chatbot? 2. How will the pharmacy chatbot impact eligible patients or caregivers on their (or the patient they are caring for) medication adherence, knowledge, and the consultation time with HA pharmacists? There will be an intervention group and a control group: 1. The intervention group will be invited to use the AI Pharmacy Chatbot online for 7 days through WhatsApp, a commonly used social media platform in Hong Kong. They can inquire about their medications prescribed under HA and get instant, validated answers from the chatbot. 2. The control group will not use the chatbot during the intervention period. To evaluate the chatbot's usability, researchers will measure patient satisfaction through usability questionnaires issued to the intervention group after their intervention period. Differences in medication adherence, medication knowledge, and HA pharmacist consultation time will also be measured between the intervention and control groups after the intervention period, to determine the chatbot's impact.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Patients aged 18 years or older diagnosed with either hyperglycaemia, hypertension, or hyperlipidaemia, and currently receiving medication prescribed by the Hospital Authority in Hong Kong. * Caregivers aged 18 years or older for patients described above. Exclusion Criteria: * There is no exclusion criterion, but they should meet the inclusion criteria above.

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-03.